Carl Zeiss Meditec AG (ETR:AFX) has received an average rating of “Hold” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is €105.71 ($122.92).
A number of research analysts have commented on AFX shares. Deutsche Bank set a €123.00 ($143.02) target price on Carl Zeiss Meditec and gave the company a “buy” rating in a research note on Monday. HSBC set a €109.00 ($126.74) target price on Carl Zeiss Meditec and gave the company a “neutral” rating in a research note on Tuesday. Kepler Capital Markets set a €80.00 ($93.02) target price on Carl Zeiss Meditec and gave the company a “sell” rating in a research note on Friday, December 6th. Nord/LB set a €132.00 ($153.49) price target on Carl Zeiss Meditec and gave the stock a “buy” rating in a research note on Wednesday. Finally, Independent Research set a €93.00 ($108.14) price target on Carl Zeiss Meditec and gave the stock a “sell” rating in a research note on Tuesday.
Shares of ETR AFX opened at €111.10 ($129.19) on Friday. The business’s 50-day moving average price is €103.92 and its two-hundred day moving average price is €98.05. The company has a debt-to-equity ratio of 4.55, a current ratio of 4.11 and a quick ratio of 3.09. Carl Zeiss Meditec has a one year low of €65.80 ($76.51) and a one year high of €112.70 ($131.05). The company has a market capitalization of $10.01 billion and a P/E ratio of 64.89.
Carl Zeiss Meditec Company Profile
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.
Featured Story: Strangles
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.